Agios Pharmaceuticals said it is discontinuing tebapivat, its next-generation oral pyruvate kinase activator, after Phase 2 data in sickle cell disease failed to demonstrate the differentiated profile needed for continued development. Agios characterized the drug as not meeting differentiation expectations, ending what was framed as the company’s primary opportunity to distinguish its enzyme-activation strategy. The decision intensifies competitive pressure at Novo Nordisk, which is advancing and has recently reported positive Phase 3 results for its own sickle cell program in this therapeutic space. Within Agios, tebapivat’s drop redirects attention to Pyrukynd (mitapivat), the company’s earlier approved enzyme activator. Agios’ earlier challenges in sickle cell underscore how difficult it has been for developers to translate incremental pharmacology into clinically meaningful differentiation in this indication.